Home ›
Colorectal Cancer Trials ›
NCT05250648
Clinical Trial on HIPEC With Mitomycin C in Colon Cancer Peritoneal Metastases (GECOP-MMC)
The aim of this study is to assess whether there are differences in PERITONEAL RECURRENCE in patients with Colon Cancer Peritoneal Metastases treated with complete surgical resection and systemic chemotherapy, with (Group 1) or without (Group 2) HIPEC with Mitomycin-C.
Trial Details
NCT ID NCT05250648
Phase PHASE4
Sponsor Hospital Universitario de Fuenlabrada
Status RECRUITING
Cancer Type Colorectal Cancer
Interventions complete cytoreductive surgery plus HIPEC with Mytomicin C for 90 minutes complete cytoreductive surgery without HIPEC
Locations (sample) Elche, Alicante, Spain|38.26218,-0.70107 Almería, Almería, Spain|36.83814,-2.45974 Badajoz, Badajoz, Spain|38.87789,-6.97061 Sant Joan Despí, Barcelona, Spain|41.36718,2.0574 Castellon, Castellón, Spain|39.98567,-0.04935
Key Eligibility Criteria
Histologically confirmed colon adenocarcinoma, except signet ring cell carcinomas (those with \> 50% of the tumor composed of these cells, which co… Absence of previously treated or current extraperitoneal metastases, including distant lymphadenopathy (retroperitoneal, mediastinal, etc), liver m… Synchronous or metachronous peritoneal metastasis of mild to moderate volume, with a PCI ≤ 20 (Appendix 2) (intraoperative confirmation). Macroscopically complete surgical cytoreduction CCS-0 (intraoperative confirmation).
For full eligibility, visit ClinicalTrials.gov .